pp-036 Nebuliser solution
Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Bronchiolitis obliterans syndrome, specifically in lung transplant patients, targeting a progressive rare inflammatory lung disease. Phase III; Inhaled liposomal formulation of cyclosporine A, delivering immunosuppression/anti-inflammatory action directly to the lung airways to halt fibrotic destruction of small airways. Unique inhaled immunosuppressive approach for BOS — no approved treatment for this indication currently.
Manufacturer #570
A pharmaceutical manufacturer based in the EU that has been active in 80+ countries selling its products for 110+ years. Main therapeutic areas include CNS, respiratory, and women’s health. Main dosage forms include sterile drugs, solid oral, and liquid forms. The company owns 20+ branches in Europe, North America, and Asia. The company possesses manufacturing facilities in Europe, Asia, and LATAM.
Manufacturer usually replies in 51 days